Medicus Pharma Ltd. Announces Unregistered Sale of Equity Securities Under Standby Equity Purchase Agreement

Key Points Investors Need to Know

• Medicus Pharma Ltd. (NASDAQ: MDCX, MDCXW) filed a Current Report on Form 8-K, dated March 6, 2026, detailing unregistered sales of equity securities.
• Unregistered Sale: The Company issued and sold 4,471,038 Common Shares to Yorkville under the Standby Equity Purchase Agreement (SEPA), with an aggregate consideration of \$3,846,910.
• Recent Sale: On March 6, 2026, Medicus Pharma sold 1,425,000 Common Shares for a consideration of \$640,110.
• Trading Details:
  • Common shares, no par value, trade under the symbol MDCX on the NASDAQ Capital Market.
  • Warrants, each exercisable for one common share at an exercise price of \$4.64 per share, trade under MDCXW on NASDAQ Capital Market.
• Use of Proceeds: Part of the net proceeds from SEPA Advances was used to prepay a portion of the debenture outstanding with Yorkville.
• Registration Exemption: Shares were issued and sold to Yorkville relying on the exemption from registration under Section 4(a)(2) of the Securities Act, based partly on representations by Yorkville.
• Future Sales: Yorkville may resell the purchased shares from time to time via an effective registration statement filed by Medicus Pharma as required by SEPA.
• Emerging Growth Company: Medicus Pharma is classified as an emerging growth company and has not elected to use the extended transition period for complying with new or revised accounting standards.
• Management: The report is signed by Dr. Raza Bokhari, Executive Chairman and CEO.

Potentially Price-Sensitive Information

• Large Share Issuance: The sale of over 4.47 million shares to Yorkville represents a significant equity issuance, which may dilute existing shareholders.
• Potential for Further Dilution: The Company retains the ability to cause Yorkville to purchase additional shares under SEPA, subject to conditions and limitations, which could further affect share supply and price.
• Warrants Outstanding: Investors should note the existence of warrants (MDCXW) that could convert into common shares at \$4.64 per share, potentially increasing the float if exercised.
• Debt Prepayment: Use of proceeds to prepay Yorkville debt reduces financial risk but also signals ongoing capital needs.
• Resale of Shares: Yorkville may sell shares into the open market, which could impact share price and liquidity depending on volume and timing.
• Regulatory Status: All shares sold to Yorkville are covered by a registration statement, enabling ongoing resale activity.

Additional Details for Shareholders

• Share Capital & Trading:
  • Medicus Pharma’s shares and warrants are listed on NASDAQ Capital Market.
  • Warrants (MDCXW) allow conversion to one common share at \$4.64, which could be attractive if the share price exceeds this level.
• Forward-Looking Statements: The company cautions that statements about future sales under SEPA, business outlook, and use of proceeds are forward-looking and subject to risks and uncertainties.
• Legal Compliance: The report expressly states it does not constitute an offer to sell or solicitation to buy any securities in jurisdictions where such actions would be unlawful.
• Exhibits: The cover page interactive data file is included as Exhibit 104.1 within the inline XBRL document.

Implications for Investors

The size and nature of the share issuance, combined with the possibility of additional sales and warrant conversions, are material events that could significantly impact Medicus Pharma’s share price and market capitalization. Current and prospective investors should monitor the volume and timing of sales by Yorkville and assess the dilution risk. The Company’s use of proceeds to pay down debt may improve its balance sheet, but ongoing capital requirements are implied.

The status as an emerging growth company may ease regulatory burdens but also introduces uncertainty as to future accounting changes and their impact.

Management Statement

The report is signed by Dr. Raza Bokhari, Executive Chairman and CEO, indicating direct oversight and responsibility for the equity issuance and capital activities.

Disclaimer

This article is based on Medicus Pharma Ltd.’s Form 8-K filed with the SEC. Forward-looking statements are subject to risks and uncertainties, including market conditions, regulatory changes, and company performance. No assurance is given as to future results or share price. Investors are advised to review official filings and consult their financial advisors before making investment decisions.

View Medicus Pharma Ltd. Historical chart here